Project Grant R15CA305329
Award Date
7/4/25
Completion Date
6/30/28
Dollars Obligated
$532K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $225,101 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Baylor College of Medicine, a private non-profit university in Houston, Texas. The grant, titled "MYCN Drives a Suppressive Tumor Immune Microenvironment in Neuroblastoma," will fund research to investigate how the MYCN oncogene reprograms T cell metabolism to create an immune-suppressive tumor microenvironment in high-risk neuroblastoma. The goal is to delineate the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $131,300 to Middle Tennessee State University to develop a novel dual inhibitor for the treatment of MYCN-amplified neuroblastoma. The key objectives are to: Identify the genes regulated by the N-MYC oncogene and its cofactors WDR5 and G9A, and determine how combined inhibition of these cofactors impacts N-MYC-dependent transcription. Pursue the identification and screening of potential...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.393 - Cancer Cause and Prevention Research) worth $718,113 to St. Jude Children's Research Hospital Inc. on January 15, 2025. The grant supports research aimed at understanding the mechanisms by which the MYC oncogenes interact with core regulatory circuitry transcription factors (CRC TFs) and epigenetic modifiers, such as histone deacetylases (HDAC) and histone lysine demethylase 4 family (KDM4), to promote neuroblastoma...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $792,367 to Nanopharmaceuticals LLC to develop a novel dual-targeting ligand, NP855, for the treatment of high-risk neuroblastoma. The key products and services to be delivered under this grant include: Scaled-up manufacturing and analytical evaluation of the NP855 drug substance to enable formulation of the drug product. In vitro and in vivo studies to confirm the efficacy of the...
This $431,968 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by Baylor College of Medicine to elucidate how the oncogene MYCN rewires the metabolic environment of neuroblastoma tumors to drive immune suppression, and to modulate this metabolic environment to enhance immune-based approaches for high-risk MYCN-amplified neuroblastoma. The research aims to uncover how MYCN amplification, a driver of aggressive neuroblastoma,...
This federal Project Grant award from the Department of Health and Human Services National Institutes of Health National Cancer Institute, under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $613,054 to St. Jude Children's Research Hospital Inc. to study the mechanisms by which transcription factors control different cell states in neuroblastoma, a high-risk pediatric tumor. The key objectives are to 1) interrogate how master transcription factors control the...
The National Cancer Institute (NCI), through the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $768,713 project grant to St. Jude Children's Research Hospital Inc. The grant, effective August 1, 2025 through July 31, 2030, will support research aimed at understanding how the histone acetyltransferase proteins EP300 and CBP control cell state plasticity and chemotherapy resistance in pediatric neuroblastoma. The project will use novel cell state reporter systems and...
This $576,659 federal Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research to investigate tumor and host immune signatures associated with disparities in outcomes following GD2 immunotherapy for patients with high-risk neuroblastoma. The primary awardee, Emory University, is collaborating with sub-awardees Dana-Farber Cancer Institute and University of Florida to: Perform tumor-based single cell genomic, proteomic, and...
The National Cancer Institute (NCI) awarded a $225,101 Project Grant (CFDA 93.396 - Cancer Biology Research) to Childrens Hospital Medical Center in Cincinnati, Ohio. The grant, titled "PanCancer Discovery and Exploration of Shared Splicing Neoantigens", will fund a comprehensive research project to create a "Splicing Neoantigen Atlas" of 30 adult and pediatric malignancies. The goal is to identify and experimentally validate diverse forms of shared splicing neoantigens...
This $503,194 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research at Seattle Children's Hospital aimed at developing an innovative multispecific T cell engager (MTE) therapy to treat neuroblastoma and other pediatric solid tumors. The key products and services being delivered under this 2-year award include: 1) Determining the efficacy of the R2P3 MTE, which binds to the ROR1 and PD-L1 tumor targets as well as CD3 on T cells,...